Long-term safety of facilitated subcutaneous immunoglobulin: Insights from a postauthorization safety study in primary immunodeficiency diseases (PID)

被引：0
|
作者：
Rubinstein, Arye [1 ,2 ]
Patel, Niraj C. [3 ]
Wedner, H. James [4 ]
Wasserman, Richard L. [5 ]
Gupta, Sudhir [6 ]
Fielhauer, Katharina [7 ]
Chavan, Shailesh [8 ]
Yel, Leman [9 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Montefiore Hosp, Bronx, NY USA
[3] Atrium Hlth, Levine Childrens Hosp, Charlotte, NC USA
[4] Washington Univ, Barnes Jewish Hosp, Sch Med, St Louis, MO USA
[5] Allergy Partners North Texas Res, Dallas, TX USA
[6] Univ Calif Irvine, Irvine, CA USA
[7] Baxalta Innovat GmbH, Vienna, Austria
[8] Shire US Inc, Lexington, MA USA
[9] Baxalta US Inc, Cambridge, MA USA
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2021年 / 26卷 / 03期
关键词：
facilitated subcutaneous immunoglobulin; real-world data; safety study; chronic inflammatory demyelinating polyradiculoneuropathy;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
65
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [21] Interim Analysis of the Global Post Authorization Safety Study of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Treatment in Patients With Primary Immunodeficiency Diseases
    Rubinstein, Arye
    Bridges, Tracy
    McNeil, Donald
    Tachdjian, Raffi
    Wedner, H. James
    Wasserman, Richard L.
    Leibl, Heinz
    Rabbat, Christopher
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (03) : 378 - 378
  • [22] LONG-TERM SAFETY AND PHARMACOKINETICS OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): PHASE 3 EXTENSION STUDY IN PRIMARY IMMUNODEFICIENCY DISEASE
    Melamed, I.
    Wasserman, R. L.
    Stein, M.
    Rubenstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 132 - 133
  • [23] Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases
    Ochs, Hans D.
    Gupta, Sudhir
    Kiessling, Peter
    Nicolay, Uwe
    Berger, Melvin
    JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (03) : 265 - 273
  • [24] Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases
    Hans D. Ochs
    Sudhir Gupta
    Peter Kiessling
    Uwe Nicolay
    Melvin Berger
    Journal of Clinical Immunology, 2006, 26 : 265 - 273
  • [25] Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies
    Gupta, Sudhir
    Kobayashi, Roger
    Melamed, Isaac
    Rehman, Syed
    Kobayashi, Ai
    Mandujano, jose-Fernando
    Geng, Bob
    Ritchie, Bruce
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB76 - AB76
  • [26] Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases
    Mach-Tomalska, Monika
    Pituch-Noworolska, Anna
    Bien, Ewa
    Malanowska, Magdalena
    Machura, Edyta
    Pukas-Bochenek, Anna
    Chrobak, Ewelina
    Pac, Malgorzata
    Pietrucha, Barbara
    Drygala, Szymon
    Kamieniak, Marta
    Kasprzak, Jakub
    Heropolitanska-Pliszka, Edyta
    IMMUNOTHERAPY, 2024, 16 (06) : 391 - 403
  • [27] Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases
    Baumann, Ulrich
    Fasshauer, Maria
    Pausch, Christine
    Wittkowski, Helmut
    Hermann, Corinna
    Pittrow, David
    Borte, Michael
    IMMUNOTHERAPY, 2022, 14 (02) : 135 - 143
  • [28] Interim Analysis of Infusion Characteristics and Adverse Events During Facilitated Subcutaneous Immunoglobulin Treatment for Primary Immunodeficiency Diseases: Global Post Authorization Safety Study
    Rubinstein, Arye
    Bridges, Tracy
    Wedner, H. James
    McNeil, Donald
    Wasserman, Richard L.
    Tachdjian, Raffi
    Fielhauer, Katharina
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2019, 39 : S53 - S54
  • [29] Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency
    Fasth, Anders
    Nystrom, Jeanette
    ACTA PAEDIATRICA, 2007, 96 (10) : 1474 - 1478
  • [30] Real-World Safety and Tolerability of Facilitated Subcutaneous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Study in Europe
    Ciznar, Peter
    Roderick, Marion
    Schneiderova, Helena
    Jesenak, Milos
    Krivan, Gergely
    Brodszki, Nicholas
    Jolles, Stephen
    Fielhauer, Katharina
    Saeed-Khawaja, Shumyla
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S97 - S98
12345